Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Day One Biopharmaceuticals, Inc.
| Metric | Day One Biopharmaceuticals, Inc. DAWNHealthcare |
|---|---|
| Quality Score | 67 / 100 |
| Revenue (latest) | $158M |
| Net income (latest) | −$107M |
| Operating margin | −80.8% |
| Net margin | −67.8% |
| Return on equity | −24.3% |
| Return on assets | −21.1% |
| Return on capital (ROCE) | −28.6% |
| Debt / equity | 0.15× |
| Revenue growth (YoY) | 20.6% |
| Altman Z″ (distress) | 6.50 |
| Accruals / assets | −0.7% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.